Funding for this research was provided by:
KWF Kankerbestrijding (UL2013-6311)
Received: 9 October 2019
Accepted: 10 February 2020
First Online: 18 February 2020
Ethics approval and consent to participate
: The STAR-TReC trial complies with the standards of the Declaration of Helsinki and current ethical guidelines and was reviewed and approved by an ethical committee (CMO region Arnhem-Nijmegen (Nijmegen), approval number NL53181.091.16). This treatment planning study is a substudy of the STAR-TReC trial (ExternalRef removed Identifier: ExternalRef removed). All patients signed written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.